8-K: Illumina Reports Q4 and Fiscal Year 2024 Results: Core Revenue Up 1%, 2025 Guidance Provided

Illumina announces its Q4 and fiscal year 2024 financial results, with core Illumina revenue up 1% in Q4 and provides guidance for fiscal year 2025.

Summary

• Illumina reported its financial results for the fourth quarter and fiscal year 2024.
• Core Illumina revenue for Q4 2024 was $1.1 billion, a 1% increase compared to Q4 2023 on both a reported and constant currency basis.
• Fiscal year 2024 core Illumina revenue reached $4.3 billion, a 2% decrease from fiscal year 2023 on both a reported and constant currency basis.
• The core Illumina GAAP operating margin for Q4 2024 was 15.8%, while the non-GAAP operating margin was 19.7%.
• For fiscal year 2024, the core Illumina GAAP operating margin was 34.0%, and the non-GAAP operating margin was 21.3%.
• Core Illumina GAAP diluted EPS for Q4 2024 was $0.73, and the non-GAAP diluted EPS was $0.95.
• For fiscal year 2024, the core Illumina GAAP diluted EPS was $5.61, and the non-GAAP diluted EPS was $4.16.
• Core Illumina generated $1.2 billion in cash from operations and $1.1 billion in free cash flow for fiscal year 2024.
• For fiscal year 2025, the company expects core Illumina constant currency revenue growth in the low single digits (reported revenue in the range of approximately $4.28 billion to $4.4 billion) and a non-GAAP operating margin of approximately 23%.
• The company anticipates a non-GAAP diluted EPS in the range of $4.50 to $4.65 for fiscal year 2025.
• Fiscal year 2024 consolidated revenue was $4.372 billion, down from $4.504 billion in fiscal year 2023.
• The company held $1.22 billion in cash, cash equivalents, and short-term investments at the end of Q4 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue growth is modest and there are some negative impacts from GRAIL, the company exceeded Q4 revenue expectations, is focused on margin expansion, and provides positive guidance for 2025.

Positives

• Core Illumina revenue saw a 1% increase in Q4 2024 compared to the same period in the previous year.
• The company's cash flow from operations remains strong, with $1.2 billion generated in fiscal year 2024.
• Illumina is focused on customer-centric innovation, margin expansion, and EPS growth.
• The company is executing a refreshed strategy that prioritizes customers and operational excellence.
• The company's gross margin increased due to cost savings and a favorable revenue mix towards sequencing consumables.
• Free cash flow was $322 million for the quarter, compared to $173 million in the prior year period.

Negatives

• Fiscal year 2024 core Illumina revenue decreased by 2% compared to fiscal year 2023.
• Consolidated revenue for fiscal year 2024 decreased to $4.372 billion from $4.504 billion in the previous year.
• The company recognized significant goodwill and IPR&D impairment charges related to GRAIL in 2024.
• The company reported a net loss of $(1,223) million for fiscal year 2024.

Risks

• The company's 2025 guidance does not reflect any potential impact from the recent China Ministry of Commerce announcement.
• Uncertainty exists regarding the impact of tariffs and trade protection measures.
• The company faces risks related to litigation arising from the GRAIL acquisition.
• The company's business is subject to changes in market growth rates, customer order volumes, and the success of competing products.
• The company's ability to achieve its financial outlook is subject to various economic and political factors.

Future Outlook

For fiscal year 2025, Illumina expects core Illumina constant currency revenue growth in the low single digits (reported revenue in the range of approximately $4.28 billion to $4.4 billion) and a non-GAAP operating margin of approximately 23%. The company expects non-GAAP diluted EPS in the range of $4.50 to $4.65.

Management Comments

• Jacob Thaysen, Chief Executive Officer, stated that Illumina delivered fourth quarter revenue that exceeded expectations and made significant progress in 2024 toward goals to drive customer-centric innovation, margin expansion, and EPS growth.
• Management will continue its transformation in 2025, executing a refreshed strategy that prioritizes a sharp focus on customers and operational excellence.

Industry Context

Illumina's results and guidance reflect the ongoing dynamics in the genomics industry, including competitive pressures, macroeconomic factors, and regulatory considerations. The collaboration with NVIDIA and investments in proteomics and genomic databases highlight the company's efforts to expand its capabilities and address emerging market opportunities.

Comparison to Industry Standards

• Illumina's revenue growth is being compared to companies such as Pacific Biosciences, which is also experiencing growth in the DNA sequencing market.
• The company's operating margin is being compared to companies such as Agilent and Danaher, which are also experiencing growth in the life sciences market.
• Illumina's EPS is being compared to companies such as Thermo Fisher Scientific, which are also experiencing growth in the life sciences market.

Stakeholder Impact

• Shareholders can expect continued focus on profitability and growth.
• Customers will benefit from customer-centric innovation and improved products and services.
• Employees will be impacted by the company's transformation and operational excellence initiatives.

Next Steps

• The company will continue to execute its refreshed strategy focused on customers and operational excellence.
• Illumina will continue to advance its NovaSeq X Series and expand its TruSight Oncology solutions.
• The company will continue to collaborate with partners like NVIDIA, Regeneron, and UK Biobank to advance scientific innovation and healthcare delivery.

Key Dates